136 related articles for article (PubMed ID: 34541974)
21. [Proteomics, a new tool for an accurate typing of amyloidosis].
Colombat M; Holifanjaniaina S; Onifarasoaniaina S; Valleix S; Maisonneuve H; Kahn JE;
Rev Med Interne; 2015 May; 36(5):346-51. PubMed ID: 25544147
[TBL] [Abstract][Full Text] [Related]
22. Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites.
Holub D; Flodrova P; Pika T; Flodr P; Hajduch M; Dzubak P
Biomed Res Int; 2019; 2019():3689091. PubMed ID: 30834260
[TBL] [Abstract][Full Text] [Related]
23. Pathology and diagnosis of renal non-AL amyloidosis.
Sethi S; Theis JD
J Nephrol; 2018 Jun; 31(3):343-350. PubMed ID: 28828707
[TBL] [Abstract][Full Text] [Related]
24. Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing.
Kaul E; Pilichowska M; Vullaganti M; Madan N; Comenzo RL
Amyloid; 2014 Mar; 21(1):62-5. PubMed ID: 24256111
[TBL] [Abstract][Full Text] [Related]
25. [Amyloid typing from formalin-fixed paraffin-embedded tissues using LMD-LC-MS/MS system].
Tasaki M; Obayashi K; Ueda M; Ando Y
Rinsho Byori; 2014 Mar; 62(3):291-6. PubMed ID: 24800507
[TBL] [Abstract][Full Text] [Related]
26. Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis.
Aoki M; Kang D; Katayama A; Kuwahara N; Nagasaka S; Endo Y; Terasaki M; Kunugi S; Terasaki Y; Shimizu A
Clin Exp Nephrol; 2018 Aug; 22(4):871-880. PubMed ID: 29372474
[TBL] [Abstract][Full Text] [Related]
27. The Clinical Implication of Incidental Prostatic Amyloidosis.
Nevo A; Muchtar E; Stern KL; Moore JP; Cheney SM; Humphreys MR; Grogan M; Stanton ML
Urology; 2020 Nov; 145():253-257. PubMed ID: 32961226
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.
Garbrecht N; Anlauf M; Schmitt A; Henopp T; Sipos B; Raffel A; Eisenberger CF; Knoefel WT; Pavel M; Fottner C; Musholt TJ; Rinke A; Arnold R; Berndt U; Plöckinger U; Wiedenmann B; Moch H; Heitz PU; Komminoth P; Perren A; Klöppel G
Endocr Relat Cancer; 2008 Mar; 15(1):229-41. PubMed ID: 18310290
[TBL] [Abstract][Full Text] [Related]
29. Two novel APOA1 gene mutations in a Japanese renal transplant recipient with recurrent apolipoprotein A-I related amyloidosis.
Horike K; Takeda A; Tsujita M; Goto N; Watarai Y; Uchida K; Katayama A; Nishihira M; Shimizu A; Nozu K; Morozumi K
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():17-21. PubMed ID: 29968409
[TBL] [Abstract][Full Text] [Related]
30. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue.
Gilbertson JA; Theis JD; Vrana JA; Lachmann H; Wechalekar A; Whelan C; Hawkins PN; Dogan A; Gillmore JD
J Clin Pathol; 2015 Apr; 68(4):314-7. PubMed ID: 25637636
[TBL] [Abstract][Full Text] [Related]
31. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.
Sethi S; Theis JD; Leung N; Dispenzieri A; Nasr SH; Fidler ME; Cornell LD; Gamez JD; Vrana JA; Dogan A
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2180-7. PubMed ID: 20876678
[TBL] [Abstract][Full Text] [Related]
32. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing.
Satoskar AA; Efebera Y; Hasan A; Brodsky S; Nadasdy G; Dogan A; Nadasdy T
Am J Surg Pathol; 2011 Nov; 35(11):1685-90. PubMed ID: 21945954
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration.
D'Souza A; Theis JD; Vrana JA; Dogan A
Amyloid; 2014 Jun; 21(2):71-5. PubMed ID: 24446896
[TBL] [Abstract][Full Text] [Related]
34. Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing.
Lavatelli F; Merlini G
Proteomics; 2018 Apr; 18(7):e1700353. PubMed ID: 29389069
[TBL] [Abstract][Full Text] [Related]
35. Systemic amyloidosis derived from EFEMP1 in a captive Tsushima leopard cat.
Miyazaki S; Kobayashi Y; Kametani F; Kobayashi K; Iwaide S; Yanai T; Murakami T
Vet Pathol; 2022 Jan; 59(1):152-156. PubMed ID: 34763604
[TBL] [Abstract][Full Text] [Related]
36. Peripheral nerve amyloidosis in sural nerve biopsies: a clinicopathologic analysis of 13 cases.
Rajani B; Rajani V; Prayson RA
Arch Pathol Lab Med; 2000 Jan; 124(1):114-8. PubMed ID: 10629141
[TBL] [Abstract][Full Text] [Related]
37. Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis.
Sethi S; Dasari S; Amin MS; Vrana JA; Theis JD; Alexander MP; Kurtin PJ
Kidney Int; 2017 Apr; 91(4):964-971. PubMed ID: 28139293
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of deposited peptides in amyloid lesions of AL amyloidosis by mass spectrometry].
Sugimoto T; Tasaki M; Yamashita T; Ueda M; Ando Y; Obayashi K; Okuno Y; Hata H
Rinsho Ketsueki; 2017; 58(6):589-594. PubMed ID: 28679987
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
40. Establishing the fluorescent amyloid ligand h-FTAA for studying human tissues with systemic and localized amyloid.
Sjölander D; Röcken C; Westermark P; Westermark GT; Nilsson KP; Hammarström P
Amyloid; 2016 Jun; 23(2):98-108. PubMed ID: 26987044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
